Anebulo Pharmaceuticals, INC Form 4 insider transactions

Director Joseph F. Lawler reports acquisition of stock options in Anebulo Pharmaceuticals.

Bimal R. Shah, a director at Anebulo Pharmaceuticals, received stock options and granted a limited power of attorney for Section 16 reporting obligations.

Kenneth C. Cundy, Chief Scientific Officer of Anebulo Pharmaceuticals, was granted stock options and has filed a power of attorney for Section 16 reporting.

Jason Aryeh, a director of Anebulo Pharmaceuticals, acquired stock options for 29,964 shares on April 4, 2025.

Richard Anthony Cunningham, CEO of Anebulo Pharmaceuticals, acquired stock options for 316,352 shares at an exercise price of $1.02 on April 4, 2025, according to a Form 4 filing.

Director Kenneth Lin acquired stock options in Anebulo Pharmaceuticals, Inc. on April 4, 2025.

Aron R. English, a director and 10% owner of Anebulo Pharmaceuticals, acquired stock options to purchase 27,647 shares of common stock on April 4, 2025.

Director Areta Kupchyk acquired stock options in Anebulo Pharmaceuticals, Inc. on April 4, 2025.

Nathaniel Calloway, a director of Anebulo Pharmaceuticals, acquired stock options on April 4, 2025.

Aron R. English, a director and 10% owner of Anebulo Pharmaceuticals, along with 22NW Fund, LP, reports the acquisition of 10,101,010 shares of common stock at $0.99 per share through a private placement.

Anebulo Pharmaceuticals CEO, Richard Anthony Cunningham, was granted 254,433 stock options on December 9, 2024, which vest immediately.

Kenneth Lin, a director at Anebulo Pharmaceuticals, reported the acquisition of stock options in a recent Form 4 filing.

Nathaniel Calloway, a director at Anebulo Pharmaceuticals, received stock options and granted power of attorney to Richard Cunningham and Daniel George for SEC reporting obligations.

Areta Kupchyk, a director at Anebulo Pharmaceuticals, was granted stock options and established a limited power of attorney for Section 16 reporting obligations.

Director Joseph F. Lawler reports the acquisition of stock options in Anebulo Pharmaceuticals, Inc.

Aron R. English, a director and 10% owner of Anebulo Pharmaceuticals, Inc., reported the acquisition of stock options in a recent Form 4 filing.

Director Bimal R. Shah acquired stock options in Anebulo Pharmaceuticals, Inc. on June 13, 2024.

Jason Aryeh, a director of Anebulo Pharmaceuticals, reports the acquisition of stock options and grants a limited power of attorney for Section 16 reporting obligations.

Kenneth C. Cundy, Chief Scientific Officer of Anebulo Pharmaceuticals, files an amended Form 4 to correct the exercise price of a stock option granted on February 29, 2024.

Kenneth C. Cundy, Chief Scientific Officer of Anebulo Pharmaceuticals, Inc., reports the acquisition of stock options.